KR20250047645A - 미만성 특발성 골격뼈 과다증(dish)의 치료, 개선, 및/또는 예방을 위한 방법 및 조성물 - Google Patents
미만성 특발성 골격뼈 과다증(dish)의 치료, 개선, 및/또는 예방을 위한 방법 및 조성물 Download PDFInfo
- Publication number
- KR20250047645A KR20250047645A KR1020247035979A KR20247035979A KR20250047645A KR 20250047645 A KR20250047645 A KR 20250047645A KR 1020247035979 A KR1020247035979 A KR 1020247035979A KR 20247035979 A KR20247035979 A KR 20247035979A KR 20250047645 A KR20250047645 A KR 20250047645A
- Authority
- KR
- South Korea
- Prior art keywords
- enpp1
- subject
- patient
- per kilogram
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325554P | 2022-03-30 | 2022-03-30 | |
| US63/325,554 | 2022-03-30 | ||
| PCT/US2022/077407 WO2023191898A1 (en) | 2022-03-30 | 2022-09-30 | Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250047645A true KR20250047645A (ko) | 2025-04-04 |
Family
ID=88202983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247035979A Pending KR20250047645A (ko) | 2022-03-30 | 2022-09-30 | 미만성 특발성 골격뼈 과다증(dish)의 치료, 개선, 및/또는 예방을 위한 방법 및 조성물 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20260041742A1 (enExample) |
| EP (1) | EP4499130A4 (enExample) |
| JP (1) | JP2025510963A (enExample) |
| KR (1) | KR20250047645A (enExample) |
| CN (1) | CN119183382A (enExample) |
| AU (1) | AU2022450370A1 (enExample) |
| CA (1) | CA3246877A1 (enExample) |
| CO (1) | CO2024014833A2 (enExample) |
| IL (1) | IL315907A (enExample) |
| MX (1) | MX2024011876A (enExample) |
| TW (1) | TW202342103A (enExample) |
| WO (1) | WO2023191898A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026102337A1 (en) | 2024-11-08 | 2026-05-15 | Biomarin Pharmaceutical Inc. | Enpp1 for use in the treatment of calciphylaxis |
| CN120163825B (zh) * | 2025-05-20 | 2025-08-08 | 青岛大学 | 一种颈椎后纵韧带骨化症自动定位及分型方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1044468A1 (zh) * | 1998-12-03 | 2002-10-25 | 海斯塔泰克有限责任公司 | 治療哮喘和炎症的小肽和方法 |
| EP1736553A1 (en) * | 2005-06-17 | 2006-12-27 | Centre National De La Recherche Scientifique | ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications |
| JP2021523139A (ja) * | 2018-05-08 | 2021-09-02 | イエール ユニバーシティ | 腎石症の進行を遅らせるための組成物および方法 |
| EP3844280A4 (en) * | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
| US20220195402A1 (en) * | 2019-04-05 | 2022-06-23 | Yale University | Enpp1 polypeptides and methods of using same |
| EP4162036A1 (en) * | 2020-06-09 | 2023-04-12 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
-
2022
- 2022-09-30 CN CN202280096064.9A patent/CN119183382A/zh active Pending
- 2022-09-30 CA CA3246877A patent/CA3246877A1/en active Pending
- 2022-09-30 EP EP22936031.8A patent/EP4499130A4/en active Pending
- 2022-09-30 IL IL315907A patent/IL315907A/en unknown
- 2022-09-30 JP JP2024557495A patent/JP2025510963A/ja active Pending
- 2022-09-30 TW TW111137435A patent/TW202342103A/zh unknown
- 2022-09-30 KR KR1020247035979A patent/KR20250047645A/ko active Pending
- 2022-09-30 WO PCT/US2022/077407 patent/WO2023191898A1/en not_active Ceased
- 2022-09-30 AU AU2022450370A patent/AU2022450370A1/en active Pending
- 2022-09-30 US US18/851,844 patent/US20260041742A1/en active Pending
-
2024
- 2024-09-26 MX MX2024011876A patent/MX2024011876A/es unknown
- 2024-10-30 CO CONC2024/0014833A patent/CO2024014833A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3246877A1 (en) | 2023-10-05 |
| CO2024014833A2 (es) | 2025-01-23 |
| EP4499130A1 (en) | 2025-02-05 |
| JP2025510963A (ja) | 2025-04-15 |
| CN119183382A (zh) | 2024-12-24 |
| EP4499130A4 (en) | 2026-03-04 |
| AU2022450370A1 (en) | 2024-10-24 |
| MX2024011876A (es) | 2025-01-09 |
| WO2023191898A1 (en) | 2023-10-05 |
| IL315907A (en) | 2024-11-01 |
| TW202342103A (zh) | 2023-11-01 |
| US20260041742A1 (en) | 2026-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240181021A1 (en) | Treatment of ENPP1 Deficiency and ABCC6 Deficiency | |
| JP2007533669A (ja) | 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法 | |
| KR20220162816A (ko) | 알칼리성 포스파타아제로 근육 약화의 치료 | |
| JP6999421B2 (ja) | 抗ソルチリン抗体及びその使用方法 | |
| US20260041742A1 (en) | Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish) | |
| US20250170223A1 (en) | Treatment of enpp1 deficiency and abcc6 deficiency | |
| BR112024019927B1 (pt) | Uso de um composto para melhorar e/ou prevenir a hiperostose esquelética idiopática difusa (dish | |
| HK40120234A (en) | Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish) | |
| KR20260058843A (ko) | 소아 enpp1 결핍증 및 abcc6 결핍증의 치료 | |
| CN116710122A (zh) | Enpp1缺乏症和abcc6缺乏症的治疗 | |
| HK40093022A (en) | Treatment of enpp1 deficiency and abcc6 deficiency | |
| WO2025255052A1 (en) | Treatment of enpp1 deficiency and abcc6 deficiency in infants | |
| JP2026516225A (ja) | アルカリホスファターゼによる筋力低下の処置 | |
| US20250073319A1 (en) | Lyophilized enpp1 polypeptide formulations and uses thereof | |
| WO2026102337A1 (en) | Enpp1 for use in the treatment of calciphylaxis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |